Thelansis’s “Primary Biliary Cholangitis (PBC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease in which immune-mediated damage to small intrahepatic bile ducts impairs bile flow. It may remain asymptomatic for years, but fatigue and pruritus are common; persistent cholestasis can lead to fibrosis, cirrhosis, and liver-related complications. Diagnosis combines cholestatic liver biochemistry with antimitochondrial antibodies or other disease-specific evidence. Ursodeoxycholic acid (UDCA) is first-line therapy, although some patients have an inadequate response or cannot tolerate it. In the United States, seladelpar and elafibranor are approved for eligible adults with an inadequate response to UDCA or intolerance to it. Symptom management and monitoring remain important, particularly for pruritus and advanced disease. Treatment gaps persist because biochemical improvement does not guarantee prevention of progression, and options remain limited for advanced disease or incomplete response.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Primary Biliary Cholangitis (PBC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Primary Biliary Cholangitis (PBC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.